14th week of 2019 patent applcation highlights part 18 |
Patent application number | Title | Published |
20190100530 | BICYCLIC KETONE COMPOUNDS AND METHODS OF USE THEREOF - The invention provides novel compounds having the general formula I: | 2019-04-04 |
20190100531 | HETEROCYCLIC COMPOUND USED AS FGFR INHIBITOR - A heterocyclic compound is described, which is an inhibitor of FGFR (fibroblast growth factor receptor). Specifically, it is a compound represented by the following formula (I), including an isomer (enantiomer or diastereomer) which may be present, or a pharmaceutically acceptable salt thereof, prodrugs, deuterated derivatives, hydrates, solvates. The definition of each group in the formula (I) is as described in the specification. The compound of the present invention has FGFR inhibitory activity and can be used for preventing or treating a disease associated with FGFR activity or expression. | 2019-04-04 |
20190100532 | PROCESS FOR PREPARING PYRIDINONE CARBOXYLIC ACID DERIVATIVES AND INTERMEDIATES - The present invention relates to the preparation of the pyridinone carboxylic acid of formula IV: | 2019-04-04 |
20190100533 | PROCESS FOR PREPARING CARBAMOYLPYRIDONE DERIVATIVES AND INTERMEDIATES - The present invention relates to the preparation of carbamoylpyridone derivatives such as the compound of formula (VI): | 2019-04-04 |
20190100534 | Cephem Compounds with Latent Reactive Groups - Cephem and penem compounds having a styrylmethylene moiety at the 3-position in the cephem or penem ring to which a positively charged leaving group is bonded and wherein the leaving group contains a vicinal diol or is bonded to a unsubstituted or substituted catechol. The leaving group can be a positively charge nitrogen leaving group. Cephems include cephalosporins, cephamycins, carbacephems, and oxacephems. Penems include penems, carbapenems and oxapenems. Preferred cephems are cephalosporins. Preferred penems are carbapenems. Compounds exhibit antibiotic activity against Gram-negative bacteria and/or Gram-positive bacteria. Compounds exhibit antibiotic activity against bacteria which exhibit multi-drug resistance. Compounds of the invention exhibit antibiotic activity against bacterial strains which produce extended spectrum beta-lactamases (ESBL), which produce AmpC beta-lactamases or which produce a carbapenemase. Pharmaceutical compositions comprising one or more cephems or penems or methods of treatment of bacterial infections with such compounds and compositions. | 2019-04-04 |
20190100535 | 6-ARYL-7-SUBSTITUTED-3-(1H-PYRAZOL-5-YL)-7H-[1,2,4]TRIAZOLO[3,4-B][1,3,4]T- HIADIAZINES AS INHIBITORS OF THE STAT3 PATHWAY WITH ANTI-PROLIFERATIVE ACTIVITY - Compounds that selectivity inhibit the STAT3 pathway and not the STAT1 pathway and exhibit anti-proliferative activity are disclosed. Also disclosed are methods of treatment of cancers that are characterized by overexpression of STAT3, which are safer that other therapies. | 2019-04-04 |
20190100536 | ANDROGEN RECEPTOR MODULATING COMPOUNDS - The present disclosure relates to compounds of formula (I), and pharmaceutically acceptable salts thereof. The present disclosure also relates to compositions and methods of treating comprising compounds of formula (I), and pharmaceutically acceptable salts thereof. | 2019-04-04 |
20190100537 | CURCUMIN-BORON COMPLEX AND PHARMACEUTICAL CONTAINING SAME - Provided is a compound which is bioapplicable and amyloid-selective, and is useful as an amyloid oxygenation catalyst applicable not only to Aβ peptides but also to other amyloids, and a preventive/therapeutic drug for an amyloid-related disease using the same. A curcumin-boron complex represented by the following formula (1): | 2019-04-04 |
20190100538 | PROCESS FOR THE PREPARATION OF BARICITINIB AND AN INTERMEDIATE THEREOF - The present invention provides processes for the preparation of baricitinib of Formula I and an intermediate of Formula V. The present invention also provides the use of the intermediate of Formula V for the preparation of baricitinib. | 2019-04-04 |
20190100539 | POLYARYLATION OF POLYHEDRAL BORANES - A polyarylborane comprising a substituted polyhedral borane comprising at least 3 exohedrally bonded aryl groups, wherein the substituted polyhedral borane is homo- or hetero-, and each exohedrally bonded aryl group is independently homo- or hetero-, substituted or unsubstituted, and monocyclic or polycyclic. Also, molecules and materials comprising the polyarylborane, and methods for making the polyarylboranes. | 2019-04-04 |
20190100540 | METHOD FOR PRODUCING MONOMER FOR SINGLE-STRANDED NUCLEIC ACID MOLECULE - A compound represented by formula (3): | 2019-04-04 |
20190100541 | DIOXOLANE ANALOGUES OF URIDINE FOR THE TREATMENT OF CANCER - The invention provides compounds of the formula: | 2019-04-04 |
20190100542 | CRYSTAL FORM OF TENOFOVIR ALAFENAMIDE SALT, PREPARATION METHOD AND USE THEREOF - Disclosed are a new polymorph II, crystal form A and B of 9-[(R)-2-[[(S)-[[(S)-1-(isopropoxycarbonyl)ethyl]amino]phenoxyphosphinyl]methoxy]propyl]adenine fumarate, and preparation methods and pharmaceutical use thereof. The crystal form II is a hemi-fumarate; the crystal form A is a mono-fumarate; and the crystal form B is a sesqui-fumarate. Compared with the existing crystal form, the new crystal forms have obvious advantages in solubility, stability and preparation process. | 2019-04-04 |
20190100543 | IRIDIUM COMPLEX AND ORGANIC ELECTROLUMINESCENCE DEVICE USING THE SAME - The present invention discloses an iridium complex of formula (1) and an organic electroluminescence device employing the iridium complex as the phosphorescent dopant material. The organic EL device can display good performance, such as lower driving voltage, reduced power consumption, increased efficiency, and longer half-life time. | 2019-04-04 |
20190100544 | ORGANIC LUMINESCENT MATERIALS CONTAINING TETRAPHENYLENE LIGANDS - Organic luminescent materials containing tetraphenylene ligands are disclosed, which can be used as emitters in the emissive layer of an organic electroluminescent device. The organic luminescent materials is metal complexes which comprise a new series of tetraphenylene ligands. The use of these novel ligands can decrease aggregation in the solid state and improve the lifetime of device. Also disclosed are an electroluminescent device and a formulation. | 2019-04-04 |
20190100545 | ORGANOMETALLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE ORGANOMETALLIC COMPOUND, AND DIAGNOSTIC COMPOSITION INCLUDING THE ORGANOMETALLIC COMPOUND - An organometallic compound represented by Formula 1: | 2019-04-04 |
20190100546 | ORGANOMETALLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE ORGANOMETALLIC COMPOUND, AND DIAGNOSTIC COMPOSITION INCLUDING THE ORGANOMETALLIC COMPOUND - An organometallic compound represented by Formula 1: | 2019-04-04 |
20190100547 | METHOD FOR PREPARING 2'-O-FUCOSYLLACTOSE - The present invention relates to a method for preparing 2′-O-fucosyllactose and to the protected fucosyl donor of the formula (I) used in this method. The method comprises reacting the fucose derivative of the formula (I) below with the compound of the general formula (II), in the presence of an activating reagent. In the formulae (I) and (II), the variables are each defined as follows: X is Br or a S-bound radical, namely —SCN, —S(O) | 2019-04-04 |
20190100548 | Anthracycline Derivatives For Treating Tumor Diseases - The invention relates to anthracycline derivative compounds for treating tumor diseases, and related methods, compositions, and kits. | 2019-04-04 |
20190100549 | FLAVONOIDE-TYPE COMPOUNDS BEARING AN O-RHAMNOSYL RESIDUE - The present invention relates to compounds of formula (II) | 2019-04-04 |
20190100550 | POLYMORPHIC FORMS OF SOFOSBUVIR - The present disclosure provides novel crystalline sofosbuvir form-M3 and a process for the preparation of sofosbuvir form-M3. The crystalline sofosbuvir form-M3 disclosed herein may be useful in the formulation of pharmaceutical dosage forms. | 2019-04-04 |
20190100551 | 5-FLUOROURIDINE MONOPHOSPHATE CYCLIC TRIESTER COMPOUNDS - Provided herein are 5-fluorouridine monophosphate cyclic triester compounds, their preparation and their uses, such as treating hepatocellular carcinoma and other types of cancer. | 2019-04-04 |
20190100552 | INHIBITORS OF PROTEIN METHYLTRANSFERASE DOT1L AND METHODS OF USE THEREOF - The present invention relates to DOT1L inhibitors and methods of identifying, designing, or optimizing them. The present invention also relates to crystals of DOT1L-inhibitor complexes, the crystal structures thereof, and the use of the crystal structures. Also disclosed are pharmaceutical compositions containing these DOT1L inhibitors and methods of treating disorders in which DOT1-mediated protein methylation plays a part, such as cancer and neurological disorders, by administering these compounds and pharmaceutical compositions to subjects in need thereof. | 2019-04-04 |
20190100553 | DIRECT ACTIVITY ASSAYS AND COMPOSITIONS FOR NUCLEOTIDE POOL SANITIZING ENZYMES - Compositions and methods are provided for detecting activity of nucleotide pool repair enzymes. In the methods of the invention, a sample suspected of having nucleotide pool repair enzyme activity is combined with a detection compound provided herein, which detection compound comprises (i) a substrate for the enzyme of interest, (ii) a polyphosphate linker; and (iii) a detection moiety that is active when released by the enzyme of interest cleaving the linker. | 2019-04-04 |
20190100554 | METHOD FOR SYNTHESIZING ETELCALCETIDE OR SALTS THEREOF - The present invention provides a method for synthesizing etelcalcetide or salts thereof, comprising the steps of: (a) synthesizing the D-amino acids in the formula (I) sequentially by Fmoc solid-phase synthesis, using a solid support as a starting material in solid phase peptide synthesis and sequentially synthesizing a D-form amino acid of formula (I) by Fmoc chemistry; deprotecting Fmoc group and acetylating the amino group to obtain a sequence A comprising protecting groups (PG) in the side chain of D-Cys and D-Arg; (b) removing the protecting group in the side-chain of D-Cys of the sequence A to form a sequence B; (c) disulfide formation at D-Cys of the sequence B by (PG)-L-Cys-OH to obtain a sequence C; (d) using a cleavage solution to remove the protecting groups of the sequence C to give etelcalcetide as formula (I). The present invention can shorten the steps and time for preparing Etelcalcetide. | 2019-04-04 |
20190100555 | EYE-CARE PEPTIDE, ITS COMPOSITION AND METHOD OF USING THE SAME - Disclosed is related to a synthetic peptide consisting of an amino acid sequence of ArgAsnProLeuGluGluThr (SEQ ID NO: 1). Also provided are a pharmaceutical composition benefic to eye care or eye health comprising the peptide, and a method for wound healing using the peptide. | 2019-04-04 |
20190100556 | PEPTIDE WITH ANTI-OBESITY AND ANTI-DIABETIC EFFICACY AND USE THEREOF - The present invention provides a peptide with an anti-obesity and/or anti-diabetic activity consisting of an amino acid sequence of SEQ ID NO: 1 or SEQ ID NO: 2. The peptide of the present invention exhibits an excellent anti-obesity effect by inhibiting fat accumulation, reducing the sizes of adipocytes, and breaking down accumulated fat through an increase in the expression of lipolytic factors pHSL and AMPK-α1, and CGI-58, and furthermore, an excellent effect on diabetes by increasing an expression of adiponectin and AMPK which effectively reduce blood glucose and improves insulin resistance, increasing the expression of glucose transporter GLUT4, and increasing an expression of IRS-1, an insulin receptor signal transduction protein. The peptide of the present invention can be effectively used for the prevention or treatment of obesity and/or diabetes. | 2019-04-04 |
20190100557 | PROTRANSDUZIN B, A GENE TRANSFER ENHANCER - An N-terminally protected peptide having the sequence | 2019-04-04 |
20190100558 | TEMPLATE-FIXED PEPTIDOMIMETICS - The template-fixed β-hairpin peptidomimetics Cyclo(-Tyr-His-Cys-Ser-Ala- | 2019-04-04 |
20190100559 | GAMMA-AAPEPTIDES WITH POTENT AND BROAD-SPECTRUM ANTIMICROBIAL ACTIVITY - The present invention is directed to a novel class of antimicrobial agents called γ-AApeptides. The current invention provides various categories of γ-AApeptides, for example, linear γ-AApeptides, cyclic γ-AApeptides, and lipidated γ-AApeptides. γ-AApeptides of the current invention are designed to exert antimicrobial activity while being stable and non-toxic. γ-AApeptides also do not appear to lead to the development of microbial resistance in treated microorganisms. Thus, the disclosed γ-AApeptides can be used for the treatment of various medical conditions associated with pathogenic microorganisms. | 2019-04-04 |
20190100560 | Ancestral Virus Sequences and Uses Thereof - Methods are described for predicting ancestral sequences for viruses or portions thereof. Also described are predicted ancestral sequences for adeno-associated virus (AAV) capsid polypeptides. The disclosure also provides methods of gene transfer and methods of vaccinating subjects by administering a target antigen opeiably linked to the AAV capsid polypeptides. | 2019-04-04 |
20190100561 | HERPES SIMPLEX VIRUS VACCINE - Herpes Simplex Virus (HSV) antigens that elicit an HSV-specific immune response and can be used to treat or prevent HSV infection are provided. Nucleic acid sequences, polypeptides, vectors, and compositions, as well as methods to induce an immune response against HSV, treat or prevent HSV disease, induce a T cell response against HSV, and induce an antibody response against HSV also are provided. | 2019-04-04 |
20190100562 | ANTIVIRAL PEPTIDE AND USE THEREFOR - An antiviral peptide provided by the present invention includes:
| 2019-04-04 |
20190100563 | PROTEINS WITH DIAGNOSTIC AND THERAPEUTIC USES - The present invention provides a recombinant protein capable of binding to complement factor H (CFH), and thereby inducing increased binding of C | 2019-04-04 |
20190100564 | Methods for Purifying Clostridial Neurotoxin - A method for purifying a clostridial neurotoxin comprising contacting a cation exchange resin with a composition comprising a clostridial neurotoxin, wherein the contacting step is performed at at least pH 7.3, wherein the step of contacting a cation exchange resin with a composition comprising said clostridial neurotoxin occurs prior to conversion of the clostridial neurotoxin from a single chain form into a dichain form. Also provided are uses of a buffer having a pH value that is −1 pH unit or higher than the calculated pi of a clostridial neurotoxin, purification intermediates and clostridial neurotoxins obtainable by the invention, wherein the clostridial neurotoxin is in a single chain form. | 2019-04-04 |
20190100565 | A TENTOXIN SYNTHESIS GENE, A METHOD FOR PRODUCING TENTOXIN OR DIHYDROTENTOXIN USING THE SAME, AND A TRANSFORMANT COMPRISING THE SAME - An object of the present invention is to identify an enzyme having activity of synthesizing dihydrotentoxin that is a tentoxin precursor and an enzyme having activity of synthesizing tentoxin using dihydrotentoxin as a substrate. The present invention concerns a tentoxin synthesis-related gene encoding a protein comprising the amino acid sequence of SEQ ID NO: 16 and having activity of nonribosomal peptide synthesis of dihydrotentoxin and a tentoxin synthesis-related gene encoding a protein comprising the amino acid sequence of SEQ ID NO: 18 and having activity of converting dihydrotentoxin to tentoxin. | 2019-04-04 |
20190100566 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST LUNG CANCER, INCLUDING NSCLC, SCLC AND OTHER CANCERS - The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules. | 2019-04-04 |
20190100567 | INTERLEUKIN-4 RECEPTOR-BINDING FUSION PROTEINS AND USES THEREOF - The present invention relates to interleukin-4 receptor binding fusion proteins. More specifically, the invention provides, in part, fusion proteins that include an interleukin-4 receptor binding protein moiety joined to a pro-apoptotic Bcl-2 family member protein moiety. | 2019-04-04 |
20190100568 | INTERLEUKIN-4 RECEPTOR-BINDING FUSION PROTEINS AND USES THEREOF - The present invention relates to interleukin-4 receptor-binding fusion proteins. More specifically, the invention provides, in part, fusion proteins that include an interleukin-4 or interleukin-13 protein moiety joined to an anti-apoptotic Bcl-2 family member protein moiety. | 2019-04-04 |
20190100569 | METHOD FOR PREPARING GLUCAGON-LIKE PEPTIDES - The present invention refers to a method for preparing a glucagon-like peptide, comprising precipitation of the peptide or of a precursor peptide by means of mixing with an anti-solvent comprising diisopropyl ether and acetonitrile. Further, the present invention also relates to a peptide conjugated to a solid phase and a pharmaceutical composition comprising a Liraglutide peptide obtainable from a method according to the present invention. | 2019-04-04 |
20190100570 | ALK4:ACTRIIB HETEROMULTIMERS AND USES THEREOF - In certain aspects, the disclosure provides soluble heteromeric polypeptide complexes comprising an extracellular domain of an ALK4 receptor and an extracellular domain of ActRIIB In certain aspects, such soluble ALK4:ActRIIB complexes may be used to regulate (promote or inhibit) growth of tissues or cells including, for example, muscle, bone, cartilage, fat, neural tissue, tumors, and/or cancerous cells. In certain aspects, such ALK4:ActRIIB complexes are can be used to improve muscle formation, bone formation, metabolic parameters, and disorders associated with these tissues, cellular networks, kidney, and endocrine systems. | 2019-04-04 |
20190100571 | CHIMERIC ANTIGEN RECEPTOR - The present invention provides a chimeric antigen receptor (CAR) comprising; (i) a B cell maturation antigen (BCMA)-binding domain which comprises at least part of a proliferation-inducing ligand (APRIL); (ii) a spacer domain (iii) a transmembrane domain; and (iv) an intracellular T cell signaling domain. The invention also provides the use of such a T-cell expressing such a CAR in the treatment of plasma-cell mediated diseases, such as multiple myeloma. | 2019-04-04 |
20190100572 | CHONDROCYTE EXTRACELLULAR MATRIX-DERIVED PEPTIDE - Disclosed is a novel peptide capable of preventing or treating ocular surface disease by inhibiting or improving pathological changes caused by neovascularization, opacification, fibrosis and inflammation of the cornea, the peptide having an amino acid sequence represented by SEQ ID NO: 1 and more particularly, provides a collagen type II α1-based peptide isolated from an animal chondrocyte cell-derived extracellular matrix and use thereof. | 2019-04-04 |
20190100573 | METHODS FOR MODIFYING HUMAN ANTIBODIES BY GLYCAN ENGINEERING - Modified Fc regions of antibodies and antibody fragments, both human and humanized, and having enhanced stability and efficacy, are provided. Fc regions with core fucose residues removed, and attached to oligosaccharides comprising terminal sialyl residues, are provided. Antibodies comprising homogeneous glycosylation of Fc regions with specific oligosaccharides are provided. Fc regions conjugated with homogeneous glycoforms of monosaccharides and trisaccharides, are provided. Methods of preparing human antibodies with modified Fc using glycan engineering, are provided. | 2019-04-04 |
20190100574 | ANTIBODIES SPECIFIC FOR ENTEROVIRUSES THAT INFECT HUMANS - This invention provides antibodies or fragments thereof that are capable of specifically binding to at least one conformational epitope of Human | 2019-04-04 |
20190100575 | BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND A STAPHYLOCOCCUS TARGET ANTIGEN AND A COMPLEMENT COMPONENT AND USES THEREOF - According to certain embodiments, the present disclosure provides bispecific antigen-binding molecules comprising a first antigen-binding domain that specifically binds a | 2019-04-04 |
20190100576 | SIGNAL BIOMARKERS - Diagnostics relating to C-type natriuretic and erythropoietin signal peptides and fragments, and kits, uses and applications therefore. | 2019-04-04 |
20190100577 | SELECTIVELY AND FULLY CLEAVABLE FLUORESCENT PROBES FOR SEQUENTIAL, ITRATIVE IMMUNOSTAINING - The subject invention provides a selectively cleavable probe comprising an F(ab) fragment linked to one or more labels by a chemically cleavable disulfide bond. | 2019-04-04 |
20190100578 | Anti-Polyubiquitin Antibodies and Methods of Use - The invention provides anti-polyubiquitin antibodies and methods of using the same. | 2019-04-04 |
20190100579 | ANTI-PACAP ANTIBODY - Antibodies to human pituitary adenylate cyclase-activating peptide, compositions comprising such antibodies, and methods of using such antibodies for the treatment of pain including headache and/or migraine. | 2019-04-04 |
20190100580 | METHOD FOR INHIBITING BONE RESORPTION - The invention is directed to a method of inhibiting bone resorption. The method comprises administering to a human an amount of sclerostin inhibitor that reduces a bone resorption marker level for at least 2 weeks. The invention also provides a method of monitoring anti-sclerostin therapy comprising measuring one or more bone resorption marker levels, administering a sclerostin binding agent, then measuring the bone resorption marker levels. Also provided is a method of increasing bone mineral density; a method of ameliorating the effects of an osteoclast-related disorder; a method of treating a bone-related disorder by maintaining bone density; and a method of treating a bone-related disorder in a human suffering from or at risk of hypocalcemia or hypercalcemia, a human in which treatment with a parathyroid hormone or analog thereof is contraindicated, or a human in which treatment with a bisphosphonate is contraindicated. | 2019-04-04 |
20190100581 | OPTIMIZED VARIANTS OF ANTI-VEGF ANTIBODIES - The present invention provides anti-VEGF antibodies and compositions that include anti-VEGF antibodies (e.g., antibody conjugates, fusion proteins, and polymeric formulations), and uses thereof, for example for treatment of disorders associated with pathological angiogenesis. The present invention also provides methods of identifying antibody variants with improved properties, for example, enhanced binding affinity, stability, pharmacokinetics, and/or expression. | 2019-04-04 |
20190100582 | COMPOSITIONS AND METHODS FOR REDUCING OCULAR NEOVASCULARIZATION - The present disclosure provides pharmaceutical compositions and methods thereof for the prevention or treatment of ocular neovascularization, such as AMD, in a subject, by administering to the subject a pharmaceutical composition comprising a rAAV vector having a nucleic acid sequence that encodes an anti-VEGF agent. | 2019-04-04 |
20190100583 | IL-17A/F HETEROLOGOUS POLYPEPTIDES AND THERAPEUTIC USES THEREOF - The present invention is directed to a novel naturally occurring human cytokine that is comprised of a heterodimer of interleukin-17 and interleukin-17F designated herein as interleukin 17A/F (IL-17A/F). Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, specific antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention. Further provided herein are methods for treating degenerative cartilaginous disorders and other inflammatory diseases. | 2019-04-04 |
20190100584 | AMINO ACID SEQUENCES DIRECTED AGAINST IL-17A, IL-17F AND/OR IL-17A/F AND POLYPEPTIDES COMPRISING THE SAME - The present disclosure relates to amino acid sequences that are directed against (as defined herein) any of IL-17A, IL-17F and/or IL-17A/F including combinations thereof, as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences. | 2019-04-04 |
20190100585 | COMPOSITIONS AND METHODS FOR TREATING RHEUMATOID ARTHRITIS - The present invention relates to the use of an anti-IL6 receptor antibody in monotherapy for treating rheumatoid arthritis and for improving the physical function and the quality of life of a subject suffering from rheumatoid arthritis. | 2019-04-04 |
20190100586 | Humanized Anti-Claudin-1 Antibodies and Uses Thereof - The present invention relates to humanized anti-claudin-1 antibodies and uses thereof. Hepatitis C virus infection is a leading cause of chronic liver disease and a major indication for liver transplantation. The tight junction protein claudin-1 (CLDN1) is an essential entry factor for HCV and a promising target for therapy. For clinical development, the inventors have humanized a rat anti-CLDN1 antibody produced by genetic immunization that prevent HCV infection and also cure chronically infected human liver chimeric mice. The lead humanized anti-CLDN1 antibody (H3L3) pan-genotypically inhibited HCV pseudoparticle infection of primary human hepatocytes (PHH) without detectable escape. H3L3 efficiently inhibited infection by diverse HCV genotype 3 strains and exhibited marked synergy with direct-acting antivirals (DAAs). The inventors also demonstrate that anti-CLDN1 H3L3 cures persistent HCV infection in human-liver chimeric uPA-SCID mice in monotherapy. Thus, the present invention relates to humanized anti-claudin-1 antibodies and uses thereof, in particular for the prevention and treatment of hepatitis C virus infection, virus-induced liver diseases, hepatocellular carcinoma (HCC), nonalcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). | 2019-04-04 |
20190100587 | IgG1 Fc MUTANTS WITH ABLATED EFFECTOR FUNCTIONS - Antibody and other Fc-containing molecules with variations in the Fc region with reduced binding to C1q and Fc gamma receptors are provided, which can be used in the treatment of various diseases and disorders. | 2019-04-04 |
20190100588 | ANTIBODY MOLECULES TO CD138 AND USES THEREOF - Antibody molecules that specifically bind to CD138 are disclosed. The antibody molecules can be used to treat, prevent, and/or diagnose disorders, such as multiple myeloma. | 2019-04-04 |
20190100589 | CANCER IMMUNOTHERAPY BY DISRUPTING PD-1/PD-L1 SIGNALING - The disclosure provides a method for immunotherapy of a subject afflicted with cancer, comprises administering to the subject a composition comprising a therapeutically effective amount of an antibody that inhibits signaling from the PD-1/PD-L1 signaling pathway. This disclosure also provides a method for immunotherapy of a subject afflicted with cancer comprising selecting a subject that is a suitable candidate for immunotherapy based on an assessment that the proportion of cells in a test tissue sample from the subject that express PD-L1 on the cell surface exceeds a predetermined threshold level, and administering a therapeutically effective amount of an anti-PD-1 antibody to the selected subject. The invention additionally provides rabbit mAbs that bind specifically to a cell surface-expressed PD-L1 antigen in a FFPE tissue sample, and an automated IHC method for assessing cell surface expression in FFPE tissues using the provided anti-PD-L1 Abs. | 2019-04-04 |
20190100590 | CANCER IMMUNOTHERAPY BY DISRUPTING PD-1/PD-L1 SIGNALING - The disclosure provides a method for immunotherapy of a subject afflicted with cancer, comprises administering to the subject a composition comprising a therapeutically effective amount of an antibody that inhibits signaling from the PD-1/PD-L1 signaling pathway. This disclosure also provides a method for immunotherapy of a subject afflicted with cancer comprising selecting a subject that is a suitable candidate for immunotherapy based on an assessment that the proportion of cells in a test tissue sample from the subject that express PD-L1 on the cell surface exceeds a predetermined threshold level, and administering a therapeutically effective amount of an anti-PD-1 antibody to the selected subject. The invention additionally provides rabbit mAbs that bind specifically to a cell surface-expressed PD-L1 antigen in a FFPE tissue sample, and an automated IHC method for assessing cell surface expression in FFPE tissues using the provided anti-PD-L1 Abs. | 2019-04-04 |
20190100591 | ANTI-TIGIT ANTIBODIES - Anti-TIGIT antibodies and antigen binding fragments thereof that inhibit TIGIT-mediated signalling are provided, together with combinations comprising said antibodies or antigen binding fragments thereof and methods for their use. | 2019-04-04 |
20190100592 | T Cell Modification and Use Thereof - This invention relates to modified T cells that inducibly express a bioactive molecule, such as IL-7, and constitutively expresses an antigen receptor, such as a T cell receptor or chimeric antigen receptor that binds to a tumour antigen. The modified T cells may comprise a nucleic acid construct that comprises a first nucleotide sequence encoding the bioactive molecule, a second nucleotide sequence encoding the antigen receptor; an inducible promoter operably linked to the first nucleotide sequence and a constitutive promoter operably linked to the second nucleotide. Nucleic acid constructs and vectors are provided, as well as T cells comprising such constructs and vectors and therapeutic methods and uses thereof. | 2019-04-04 |
20190100593 | COMPOSITIONS AND METHODS FOR NON-MYELOABLATIVE CONDITIONING - Disclosed herein are non-myeloablative antibody-toxin conjugates and compositions that target cell surface markers, such as the CD34, CD45 or CD117 receptors, and related methods of their use to effectively conditioning a subject's tissues (e.g., bone marrow tissue) prior to engraftment or transplant. The compositions and methods disclosed herein may be used to condition a subject's tissues in advance of, for example, hematopoietic stem cell transplant and advantageously such compositions and methods do not cause the toxicities that are commonly associated with traditional conditioning methods. | 2019-04-04 |
20190100594 | MULTIVALENT AND MULTISPECIFIC GITR-BINDING FUSION PROTEINS - This disclosure generally provides molecules that specifically engage glucocorticoid-induced TNFR-related protein (GITR), a member of the TNF receptor superfamily (TNFRSF). More specifically, the disclosure relates to multivalent and/or multispecific molecules that bind at least GITR. | 2019-04-04 |
20190100595 | ANTIBODY POLYPEPTIDES THAT ANTAGONIZE CD40L - Antibody polypeptides that specifically bind human CD40L are provided. The antibody polypeptides do not activate platelets. The antibody polypeptides are useful in the treatment of diseases involving CD40L activation, such as graft-related diseases and autoimmune diseases. The antibody polypeptides may be domain antibodies (dAbs) comprising a single V | 2019-04-04 |
20190100596 | ANTI-OX40 ANTIBODIES AND METHODS OF USING THE SAME - Human antibodies, preferably recombinant human antibodies, both humanized and chimeric, which specifically bind to human OX40 are disclosed. Preferred antibodies have high affinity for OX40 receptor and activate the receptor in vitro and in vivo. The antibody can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, are useful for modulating receptor activity, e.g., in a human subject suffering from a disorder in which OX40 activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies are provided, and methods of synthesizing the recombinant human antibodies, are also provided. | 2019-04-04 |
20190100597 | CD20 BINDING MOLECULES AND USES THEREOF - This disclosure provides pentameric and hexameric CD20 binding molecules and methods of using such molecules to direct complement-mediated, T-cell-mediated, or both complement-mediated and T-cell-mediated killing of CD20-expressing cells. | 2019-04-04 |
20190100598 | ANTI-KIT ANTIBODIES AND USES THEREOF - Provided herein, in one aspect, are antibodies that immunospecifically bind to a human KIT antigen comprising the fourth and/or fifth extracellular Ig-like domains (that is, D4 and/or D5 domains), polynucleotides comprising nucleotide sequences encoding such antibodies, and expression vectors and host cells for producing such antibodies. The antibodies can inhibit KIT activity, such as ligand-induced receptor phosphorylation. Also provided herein are kits and pharmaceutical compositions comprising antibodies that specifically bind to a KIT antigen, as well as methods of treating or managing a KIT-mediated disorder or disease and methods of diagnosing a KIT-mediated disorder or disease using the antibodies described herein. | 2019-04-04 |
20190100599 | NANOBODY DIMERS LINKED VIA C-TERMINALLY ENGINEERED CYSTEINS - The present invention relates to dimers comprising a first polypeptide and a second polypeptide, wherein each of said first and second polypeptide comprises at least one immunoglobulin single variable domain (ISVD) and a C-terminal extension comprising a cysteine moiety (preferably at the C-terminus), wherein said first polypeptide and said second polypeptide are covalently linked via a disulfide bond between the cysteine moiety of said first polypeptide and the cysteine moiety of said second polypeptide, in which the dimer outperformed the benchmark constructs, e.g. cognate multivalent and multispecific constructs, in various assays. The present invention provides methods for making the dimers of the invention. | 2019-04-04 |
20190100600 | ADMINISTRATION OF AN ANTI-LGR5 MONOCLONAL ANTIBODY - The present invention relates generally to the field of cancer biology. Some embodiments of the methods and compositions provided herein relate to administration of humanized antibodies or antigen-binding fragments thereof that specifically bind to LRG5 to treat certain cancers | 2019-04-04 |
20190100601 | MONOCLONAL ANTIBODY THERAPY FOR PANCREAS CANCER - The present invention relates to the use of binding equivalents of monoclonal antibody 31.1, including chimerized and/or humanized versions thereof, antibody fragments as well as competitively binding and co-specific antibodies and antibody fragments, in the treatment of pancreatic cancer. | 2019-04-04 |
20190100602 | ANTI-ANTITHROMBIN SINGLE-DOMAIN ANTIBODIES AND POLYPEPTIDES COMPRISING THEREOF - The present invention relates to isolated single-domain antibodies (sdAb) directed against Antithrombin (AT) to prolong the half-life of the proteins. Inventors have generated isolated single domain antibodies (sdAbs) directed against antithrombin. They observed that in amidolytic assays, sdAbs are incapable of blocking the inhibitory antithrombin activity towards thrombin and factor Xa in the presence of heparin. The different combinations of sdAb were able to block the inhibitory antithrombin activity towards thrombin and factor Xa in mice. Thus, the inventors propose to use different combinations of sdAb to block the inhibitory function of antithrombin in order to promote thrombin generation and thus treat haemophilia and other conditions that are associated with bleeding. Accordingly, the invention relates also to a method of preventing or treating bleeding disorders in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of the single domain antibodies or the drug conjugate of the invention. | 2019-04-04 |
20190100603 | HETERODIMERIC PROTEINS AND METHODS FOR PRODUCING AND PURIFYING THEM - The present invention relates to engineered heteromultimeric proteins, and more specifically, to methods for producing and purifying heterodimeric proteins, such as bispecific antibodies and other heterodimeric proteins comprising immunoglobulin-like hinge sequences. Methods for producing and purifying such engineered heterodimeric proteins and their use in diagnostics and therapeutics are also provided. | 2019-04-04 |
20190100604 | PROCESSES AND APPARATUS FOR PRODUCING NANOCELLULOSE, AND COMPOSITIONS AND PRODUCTS PRODUCED THEREFROM - Processes disclosed are capable of converting biomass into high-crystallinity nanocellulose with surprisingly low mechanical energy input. In some variations, the process includes fractionating biomass with an acid (such as sulfur dioxide), a solvent (such as ethanol), and water, to generate cellulose-rich solids and a liquid containing hemicellulose and lignin; and mechanically treating the cellulose-rich solids to form nanofibrils and/or nanocrystals. The crystallinity of the nanocellulose material may be 80% or higher, translating into good reinforcing properties for composites. The nanocellulose material may include nanofibrillated cellulose, nanocrystalline cellulose, or both. In some embodiments, the nanocellulose material is hydrophobic via deposition of some lignin onto the cellulose surface. Optionally, sugars derived from amorphous cellulose and hemicellulose may be separately fermented, such as to monomers for various polymers. These polymers may be combined with the nanocellulose to form completely renewable composites. | 2019-04-04 |
20190100605 | MODIFIED HYALURONIC ACID, METHOD FOR MAKING SAME AND USES THEREOF - The present invention generally relates to a modified hyaluronic acid (HA) and to a method for making same, more specifically to a (poly)glycerol-modified HA derivative prepared by grafting glycidol to HA. The present invention also relates to the use of the HA derivative for preparing a dermal filler composition, a hydrogel comprising cross-linked HA and the (poly)glycerol-modified HA derivative, and a method for preparing said hydrogel. Furthermore, the present invention relates to the use of the hydrogel as a cosmetic and/or aesthetic product, in particular as a dermal filler for tissue filling, replacing and/or augmenting. | 2019-04-04 |
20190100606 | Dual Catalyst System for Producing LLDPE Copolymers with Improved Processability - Disclosed herein are ethylene-based polymers generally characterized by a density from 0.89 to 0.93 g/cm | 2019-04-04 |
20190100607 | POLYVINYL ALCOHOL - A polyvinyl alcohol has a number-average molecular weight (Mn) from 4,400 to 440,000, a molecular weight distribution (Mw/Mn) from 1.05 to 1.70, a degree of saponification from 80 to 99.99 mol %, and a carbon-carbon double bond content (X) of 0.1 mol % or less based on total monomer units, and satisfying a formula (1) below. A polyvinyl alcohol, having a narrow molecular weight distribution and a high number-average molecular weight with good hue, and a method for producing the same are thus provided. | 2019-04-04 |
20190100608 | PHOTOCURABLE RESIN COMPOSITION AND CURED PRODUCT OF SAME - The objection of the present invention is to provide a photocurable resin composition having deep curability. The photocurable resin composition comprises an allyl polymer (a) produced by polymerization of an allyl compound represented by the following formula (1), a photocurable compound (b), and a photopolymerization initiator (c). In the formula, n represents an integer of 2 to 4; Z is selected from a binding site, an n-valent aliphatic chain hydrocarbon group optionally having a hydroxyl group, an n-valent alicyclic hydrocarbon group optionally having an alkyl group, and an n-valent aromatic hydrocarbon group optionally having an alkyl group; n is 2 and two —COOCH | 2019-04-04 |
20190100609 | BUTENE-1 POLYMER IN MASTERBATCH, CONCENTRATE, AND COMPOUNDING APPLICATIONS - One or more 1-butene polymers and uses thereof. The 1-butene polymer may be used as a viscosity modifier, flexibilizer, dispersing aid, and/or impact modifier for polymer compositions, such as those including polypropylene. The 1-butene polymer may also be used as a carrier for additives, such as fluorinated additives. Articles may be made that include the 1-butene polymer, polypropylene, and pigments. | 2019-04-04 |
20190100610 | ETHYLENE-VINYL ALCOHOL COPOLYMER AND PROCESS FOR PRODUCING SAID ETHYLENE-VINYL ALCOHOL COPOLYMER - The present invention provides an ethylene-vinyl alcohol copolymer which can be melt-molded at lower temperatures than conventional ethylene-vinyl alcohol copolymers to give molded objects that are inhibited from suffering undesirable coloration or having fish-eyes and that have excellent gas barrier properties. The ethylene-vinyl alcohol copolymer of the invention has a carboxylic acid ester group at a polymer terminal. | 2019-04-04 |
20190100611 | Ethylene/1-hexene Copolymer Having Excellent Processability And Mechanical Properties - The ethylene/1-hexene copolymer according to the present invention has excellent processability and mechanical properties, and thus can be applied to various fields such as food containers. | 2019-04-04 |
20190100612 | MODIFIED HYDROCARBON RESIN AND HOT MELT ADHESIVE COMPOSITION - Provided is a modified hydrocarbon resin that provides a hot melt adhesive composition with low odor, excellent heat stability, and high adhesive properties. The modified hydrocarbon resin is obtained by hydrogenating a hydrocarbon resin comprising a plurality of specific monomeric unit in a specific range, and characterized in that: a degree of hydrogenation of the olefins, a degree of hydrogenation of the aromatic rings, a weight average molecular weight (Mw), a Z-average molecular weight (Mz), a ratio (Mz/Mw) of the Z-average molecular weight to the weight-average molecular weight, a Gardner color scale of a toluene solution of 50 mass %, and a difference between pre-hydrogenation and post-hydrogenation mixed aniline point (MMAP) are within the specific range. | 2019-04-04 |
20190100613 | FINELY DIVIDED AQUEOUS MULTISTAGE POLYMER DISPERSION, METHOD FOR THE PRODUCTION THEREOF, AND USE THEREOF AS A BINDER - The present invention provides very finely divided polymer dispersions obtainable by at least one two-stage emulsion polymerization, wherein
| 2019-04-04 |
20190100614 | POLYMERIZABLE COMPOSITION FOR OPTICAL MATERIAL AND OPTICAL MATERIAL AND PLASTIC LENS OBTAINABLE FROM SAME COMPOSITION - A polymerizable composition for an optical material according to the present invention includes one or two or more compounds selected from the group consisting of component (A): an ester compound having a specific structure and component (B): an ether compound having a specific structure, and a polymerizable compound. | 2019-04-04 |
20190100615 | BLOCKED POLYISOCYANATE COMPOSITION, ONE-COMPONENT COATING COMPOSITION, COATING FILM, AND COATED ARTICLE - The present invention provides a blocked polyisocyanate composition comprising a blocked polyisocyanate formed through blocking at least a part of isocyanate groups possessed by a polyisocyanate derived from one or two or more diisocyanates selected from the group consisting of an aliphatic diisocyanate and an alicyclic diisocyanate with an active methylene-based compound comprising a malonic acid diester, wherein a specific molar ratio calculated from contents (mol %) of isocyanurate groups, iminooxadiazinedione groups, uretdione groups, and allophanate groups is 0.05 or more and 0.60 or less. | 2019-04-04 |
20190100616 | Blend For Curing Epoxy Resin Composistions - The present disclosure provides a curable composition that includes an epoxy resin and a curing component comprising a blend of at least two amines. The curable composition may be combined with reinforced fibers and cured to form a composite article which can be used in various applications, such as in wind turbine blades. | 2019-04-04 |
20190100617 | POLYMERIZABLE COMPOSITION BASED ON ALLYL CARBONATE MONOMERS, POLYMERIZED PRODUCT OBTAINABLE FROM SAID COMPOSITION AND USES THEREOF - The present invention relates to a polymerizable composition based on allyl carbonate monomers comprising: —from 40% to 90% of a first reactive component (component A) comprising at least 50% by weight of diethylene glycol bis(allyl carbonate);
| 2019-04-04 |
20190100618 | High Modulus Curable Composition - The invention relates to a curable composition comprising a) at least one polymer having at least one terminal group of the general formula (I) | 2019-04-04 |
20190100619 | PROCESS FOR THE SYNTHESIS OF (PER)FLUOROPOLYETHER AMINES - A process for the manufacture of a (per)fluoropolyether amine comprising reacting a sulfonic ester of a (per)fluoropolyether alcohol with an excess of ammonia or organic amine at selected temperature is herein disclosed. The process allows obtaining (per)fluoropolyether amines, in particular primary, secondary and tertiary (per)fluoropolyether amines with high yields and selectivity and can be conveniently applied on an industrial scale. | 2019-04-04 |
20190100620 | ACRYLATE-TERMINATED URETHANE POLYBUTADIENES FROM LOW-MONOMER 1:1 MONOADDUCTS FROM REACTIVE OLEFINIC COMPOUNDS AND DIISOCYANATES AND HYDROXY-TERMINATED POLYBUTADIENES FOR LIQUID OPTICALLY CLEAR ADHESIVES (LOCAs) - The present invention relates to a process for producing hydrosilylatable, eugenol-based polyethers, to the conversion thereof into polyether siloxanes and also to the products that may be produced by this process and to the use of said products as surfactants. | 2019-04-04 |
20190100621 | NOVEL POLYMER HAVING ALDARIC ACID AS CONSTITUTIONAL UNIT AND METHOD FOR PRODUCING SAME - The present invention relates to a high molecular weight polymer having an aldaric acid as a constitutional unit, and a method for producing the same, and more specifically, relates to a thermoplastic polymer which comprises at least one repeating unit derived from an aldaric acid, and has a weight average molecular weight of 3,800 or more. | 2019-04-04 |
20190100622 | METHOD FOR CONTROLLING POLYIMIDE BACKBONE STRUCTURE AND METHOD FOR PRODUCING POLYIMIDE - A method for controlling a polyimide backbone structure, including: in preparation of a polyimide through reaction of a diamine component and (1S,2R,4S,5R)-cyclohexanetetracarboxylic dianhydride in an organic solvent containing an aprotic amide solvent and a lactone solvent, adjusting one or more of reaction conditions of a mass ratio of the aprotic amide solvent and the lactone solvent, a reaction temperature, a reaction time, and an amount of the aprotic amide solvent, so as to convert a cis-structure derived from the (1S,2R,4S,5R)-cyclohexanetetracarboxylic dianhydride in the formed polyimide to a trans-structure derived from (1R,2S,4S,5R)-cyclohexanetetracarboxylic dianhydride corresponding to the reaction conditions, thereby controlling a proportion of the trans-structure. | 2019-04-04 |
20190100623 | COMPOSITE ARTICLE FROM REACTIVE PRECURSOR MATERIAL - A method comprises preparing or receiving a polyetherimide precursor solution including (i) a solvent comprising water, aliphatic alcohol, or a mixture thereof; (ii) an amine additive comprising a secondary or tertiary amine; and (iii) a polyetherimide precursor dissolved and dissociated in the solvent. The method further comprises at least partially coating or impregnating one or more reinforcement structures with the polyetherimide precursor solution and polymerizing the one or more polyetherimide precursor reagents to form a polyetherimide matrix such that the one or more reinforcement structures are at least partially embedded in the polyetherimide matrix to provide a composite article. | 2019-04-04 |
20190100624 | POLYAMIDE ACID, THERMOPLASTIC POLYIMIDE, RESIN FILM, METAL-CLAD LAMINATE AND CIRCUIT BOARD - A polyamide acid which contains at least one diamine compound selected from among diamine compounds represented by general formula (8) within the range of 3-60 parts by mole in total per 100 parts by mole of all diamine components, while containing a biphenyl tetracarboxylic acid dianhydride within the range of 40-100 parts by mole and a pyromellitic acid dianhydride within the range of 0-60 parts by mole per 100 parts by mole of all acid anhydride components; and a thermoplastic polyimide which is obtained curing this polyamide acid. | 2019-04-04 |
20190100625 | MIXTURES OF CYCLIC BRANCHED SILOXANES OF THE D/T TYPE AND CONVERSION PRODUCTS THEREOF - Mixtures of cyclic branched siloxanes having exclusively D and T units and having no functional groups, with the proviso that the cumulative proportion of the D and T units having Si-alkoxy and/or SiOH groups that are present in the siloxane matrix, determinable by | 2019-04-04 |
20190100626 | SILICONE FORMULATIONS FOR 3D PRINTING - In one embodiment, a silicone-based ink for additive manufacturing includes a vinyl-terminated siloxane macromer, a hydrophobic reinforcing filler, and a rheology modifying additive. In another embodiment, a method of additive manufacturing with silicone-based ink includes adding a mixture that includes a vinyl-terminated siloxane macromer, a hydrophobic reinforcing filler, and a rheology modifying additive to a cartridge for additive manufacturing, extruding the mixture through the cartridge to form a structure, and curing the mixture to at least a predefined extent. | 2019-04-04 |
20190100627 | Super Absorbent Polymer - The present invention relates to a superabsorbent polymer exhibiting excellent heat stability. | 2019-04-04 |
20190100628 | ALGINATE HYDROGEL COMPOSITIONS - The present application provides a semi-permeable hydrogel composition comprising an alginate matrix that is covalently crosslinked in its periphery to a multi-armed water soluble polymer, along with related methods and uses thereof. | 2019-04-04 |
20190100629 | Super Absorbent Polymer And Method For Producing Same - A super absorbent polymer according to the present invention has an excellent discoloration resistance characteristic even under high temperature/high humidity conditions, while maintaining excellent absorption performance, and is preferably used for hygienic materials such as diapers, and thus can exhibit excellent performance. | 2019-04-04 |